Eli Lilly receives FDA approval for multi-dose Zepbound injection pen in the United States
Eli Lilly received FDA approval today for a multi-dose KwikPen to deliver its weight-loss drug Zepbound. The device provides a full month of treatment.
洞察:
The U.S. Food and Drug Administration has granted approval to Eli Lilly and Company for a four-dose KwikPen delivery system for its weight-loss medication, Zepbound. Announced on February 23, 2026, this authorization allows a single device to deliver a full month of treatment within the US 
US. The introduction of the multi-dose KwikPen is expected to alter how the drug is supplied and priced in the American market, providing a new structural option for healthcare providers and patients.
US. The introduction of the multi-dose KwikPen is expected to alter how the drug is supplied and priced in the American market, providing a new structural option for healthcare providers and patients.
